Dear Dr Knight,

Re: NICE STA – Belimumab for the treatment of patients with SLE

Please accept this letter as confirmation that the final list vial prices for belimumab, which have been ratified through the PPRS procedure, are as follows:

120mcg vial = £121.50
400mcg vial = £405.00

We have submitted a patient access scheme (PAS) with our STA submission, which has been accepted by the Department of Health. This PAS offers a straight discount of approximately *** on the belimumab vial acquisition cost. Incorporation of the PAS discount for our proposed high disease activity target population, based on the weight distribution seen for these patients in the two Phase 3 BLISS randomised controlled trials, provides the following vial prices:

120mcg vial = £***
400mcg vial = £***.00

Kind Regards

[Signature]

Health Outcomes Department
GlaxoSmithKline UK Ltd
Stockley Park West
Uxbridge
UB11 1BT
Tel: [Redacted]